3 transcripts
DVAX
Earnings call transcript
NASDAQ
2024 Q1
8 May 24
margin of approximately 80% for the full year of 2024. We expect R&D expenses to be between approximately $60 million and $75 million. We expect SG
DVAX
Earnings call transcript
NASDAQ
2023 Q4
22 Feb 24
investments to drive the HEPLISAV-B market opportunity, continuing to advance R&D efforts, and pursuing new opportunities to accelerate our growth
DVAX
Earnings call transcript
NASDAQ
2023 Q2
3 Aug 23
of capital is sufficient to support our core business, enabling us to drive sustainable growth in help to capture a majority market share and bring our R&D portfolio
- Prev
- 1
- Next